Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Inhibikase Therapeutics

29/03/2024 13:31

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-1.08.  The mean expectation of
two analysts for the quarter was for a loss of 85 cents per
share. Wall Street expected results to range from -92 cents
to -78 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 64 cents​.
    * The company reported a quarterly loss of $4.18 million.
    * Inhibikase Therapeutics Inc shares had risen by 81.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 27.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $17.50 

This summary was machine generated from LSEG data March 29 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.85          -0.64          Beat
 Sep. 30 2023      -1.12          -0.86          Beat
 Jun. 30 2023      -0.92          -1.11          Missed
 Mar. 31 2023      -0.87          -0.96          Missed